Phase II clinical trials of dovitinib, a multi‐targeted RTK inhibitor that prevents phosphorylation of FGFR3, showed limited activity in advanced bladder cancer 25 and in BCG‐unresponsive bladder cancer with mutations or overexpression of FGFR3 26. Here, FGFR3 is linked to urinary bladder cancer.